Mismatch repair deficiency predicts response of solid tumors to PD-1 blockadeDung T. Le, Luis A. Díaz, Agnieszka A. Rucki et al.|Science|2017Cited by 6.6k
NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019Deborah K. Armstrong, Anita M. Engh, Ronald D. Alvarez et al.|Journal of the National Comprehensive Cancer Network|2019Cited by 332
A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian CancerAmit M. Oza, Daniela Matei, Ursula A. Matulonis et al.|Clinical Cancer Research|2019Cited by 90
A final report of a phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy (LDFWAR) in patients with advanced solid malignancies and peritoneal carcinomatosis with a dose escalation in ovarian and fallopian tube cancersKim A. Reiss, Nilofer S. Azad, Joseph M. Herman et al.|Gynecologic Oncology|2017Cited by 53
Data from A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian CancerAmit M. Oza, Daniela Matei, Ursula A. Matulonis et al.|Unknown|2023Cited by 1